Circulating Liver-enriched Antimicrobial Peptide-2 Decreases During Male Puberty.
acylated ghrelin
liver-enriched antimicrobial peptide-2
puberty
testosterone
Journal
Journal of the Endocrine Society
ISSN: 2472-1972
Titre abrégé: J Endocr Soc
Pays: United States
ID NLM: 101697997
Informations de publication
Date de publication:
01 Mar 2022
01 Mar 2022
Historique:
received:
04
12
2021
entrez:
21
2
2022
pubmed:
22
2
2022
medline:
22
2
2022
Statut:
epublish
Résumé
Circulating levels of liver-enriched antimicrobial peptide 2 (LEAP2), a ghrelin receptor antagonist, decrease under caloric restriction and increase in obesity. The role of LEAP2 in male puberty, a phase with accelerated energy demand, is unclear. This work aimed to investigate whether circulating LEAP2 levels are downregulated in boys following the onset of puberty to respond to the energy need required for growth. We determined circulating LEAP2 levels in 28 boys with constitutional delay of growth and puberty (CDGP) who participated in a randomized controlled trial (NCT01797718), and were treated with letrozole (n = 15) or intramuscular low-dose testosterone (T) (n = 13) for 6 months. Blood sampling and dual-energy x-ray absorptiometry-measured body composition were performed at 0-, 6-, and 12-month visits. Serum LEAP2 levels decreased statistically significantly during pubertal progression (0-6 months: mean decrease -4.3 [10.3] ng/mL, Circulating LEAP2 levels decreased after induction of puberty reciprocally with increased growth rate and energy demand, reflecting the metabolic state of the adolescent. Further, the results suggest that estradiol levels may have a permissive role in downregulating circulating LEAP2 levels.
Identifiants
pubmed: 35187383
doi: 10.1210/jendso/bvac013
pii: bvac013
pmc: PMC8852683
doi:
Types de publication
Journal Article
Langues
eng
Pagination
bvac013Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society.
Références
Pediatr Endocrinol Rev. 2005 Mar;2(3):383-90
pubmed: 16429115
J Adolesc Health. 2002 Dec;31(6 Suppl):192-200
pubmed: 12470915
J Clin Endocrinol Metab. 2014 Nov;99(11):E2198-206
pubmed: 25137423
Front Endocrinol (Lausanne). 2021 Aug 24;12:717544
pubmed: 34512549
J Clin Invest. 2019 Sep 3;129(9):3909-3923
pubmed: 31424424
Clin Endocrinol (Oxf). 2022 Feb;96(2):220-226
pubmed: 34596269
Pediatr Obes. 2020 Dec;15(12):e12685
pubmed: 32614151
Mol Metab. 2015 Mar 21;4(6):437-60
pubmed: 26042199
Ann Med. 2011 May;43(3):235-48
pubmed: 20854213
J Endocrinol. 2020 Jan 1;244(1):13-23
pubmed: 31539874
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
Diabetes. 2007 Apr;56(4):1051-8
pubmed: 17251274
J Clin Invest. 2006 Mar;116(3):760-8
pubmed: 16511605
Mol Metab. 2021 Nov;53:101327
pubmed: 34428557
Eur J Nutr. 2000 Aug;39(4):157-63
pubmed: 11079735
Nature. 1999 Dec 9;402(6762):656-60
pubmed: 10604470
FEBS J. 2021 Dec;288(24):7213-7229
pubmed: 33460513
IUBMB Life. 2021 Jul;73(7):978-984
pubmed: 33991145
Neuron. 2003 Feb 20;37(4):649-61
pubmed: 12597862
Int J Obes (Lond). 2021 Mar;45(3):502-514
pubmed: 33139887
Lancet Child Adolesc Health. 2019 Feb;3(2):109-120
pubmed: 30612946
Cell Metab. 2018 Feb 6;27(2):461-469.e6
pubmed: 29233536
J Clin Endocrinol Metab. 2006 Jun;91(6):2081-6
pubmed: 16551727
Vitam Horm. 2008;77:47-88
pubmed: 17983853
Am J Clin Nutr. 2019 Apr 1;109(4):1154-1163
pubmed: 30869114
Eur J Endocrinol. 2011 Aug;165(2):233-41
pubmed: 21646290
Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4679-84
pubmed: 15070777
J Clin Endocrinol Metab. 2019 Jul 1;104(7):2777-2784
pubmed: 30860584
Nature. 2001 Jan 11;409(6817):194-8
pubmed: 11196643
J Clin Endocrinol Metab. 2002 Mar;87(3):1041-4
pubmed: 11889159
J Med Chem. 2019 Jan 24;62(2):965-973
pubmed: 30543423